The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
The role of pharmacokinetics/pharmacodynamics in setting clinical MIC breakpoints: the EUCAST approach
Open accessAbstract
Clinical breakpoints are used in clinical microbiology laboratories to categorize microorganisms as clinically susceptible (S), intermediate (I) or resistant (R) dependent on the quantitative antimicrobial susceptibility as indicated by the MIC value determined in a well-defined standard test system. The laboratory report, with the designations of S, I or R for each antimicrobial agent, provides guidance to clinicians with respect to the potential use of agents in the treatment of patients, and clinical breakpoints should therefore distinguish between patients that are likely or unlikely to respond to antimicrobial treatment. In Europe, clinical breakpoints are set by the European Committee on Antimicrobial Susceptibility Testing (EUCAST), following a defined procedure. This includes evaluation of efficacy in experimental settings and clinical studies to derive pharmacodynamic targets such as the fAUC/MIC ratio or %fT > MIC required for efficacy, the pharmacokinetic properties of the agent, Monte Carlo simulations to estimate exposures of the antimicrobial agent in the target patient population and commonly used dosing regimens. The probability of target attainment is subsequently determined for a range of pharmacodynamic targets and the results from the Monte Carlo simulations. The breakpoints derived are subsequently evaluated with respect to the wild-type population of the target microorganisms, specific resistance mechanisms and other relevant data. In this paper, we provide an overview of the EUCAST process and considerations for setting pharmacokinetic/pharmacodynamic breakpoints. These are the breakpoints that in the EUCAST breakpoint tables are referred to as 'non-species-related breakpoints'.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Craig, W. A. (1998) · Clinical Infectious Diseases · doi:10.1086/516284 · Cited by 2,908 · cited 1×
“The PDT is therefore most often derived from preclinical studies, such as studies in animal models [18,19], but in vitro hollow fibre infection models [20–22] are increasingly used.”
Ambrose, P. G., Bhavnani, S. M., Rubino, C. M., Louie, A., Gumbo, T., Forrest, A., & Drusano, G. L. (2007) · Clinical Infectious Diseases · doi:10.1086/510079 · Cited by 697
EUCAST expert rules in antimicrobial susceptibility testing
Leclercq, R., Cantón, R., Brown, D. F. J., Giske, C. G., Heisig, P., MacGowan, A. P., Mouton, J. W., Nordmann, P., Rodloff, A. C., Rossolini, G. M., et al. (2013) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2011.03703.x · Cited by 683
Self-citationCraig, W. A. (2003) · Infectious Disease Clinics of North America · doi:10.1016/s0891-5520(03)00065-5 · Cited by 556
Mouton, J. W., Dudley, M. N., Cars, O., Derendorf, H., & Drusano, G. L. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki079 · Cited by 549
Self-citationEuropean harmonization of MIC breakpoints for antimicrobial susceptibility testing of bacteria
Kahlmeter, G. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg312 · Cited by 397
Self-citationOptimizing Aminoglycoside Therapy for Nosocomial Pneumonia Caused by Gram-Negative Bacteria
Kashuba, A. D. M., Nafziger, A. N., Drusano, G. L., & Bertino, J. S. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.3.623 · Cited by 380
Roberts, J. A., Kirkpatrick, C. M. J., Roberts, M. S., Robertson, T. A., Dalley, A. J., & Lipman, J. (2009) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkp139 · Cited by 347
Ambrose, P. G., Grasela, D. M., Grasela, T. H., Passarell, J., Mayer, H. B., & Pierce, P. F. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.10.2793-2797.2001 · Cited by 299
A Brief Introduction to Monte Carlo Simulation
Bonate, P. L. (2001) · Clinical Pharmacokinetics · doi:10.2165/00003088-200140010-00002 · Cited by 243
Drusano, G. L., Preston, S. L., Hardalo, C., Hare, R., Banfield, C., Andes, D., Vesga, O., & Craig, W. A. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.1.13-22.2001 · Cited by 243
Firsov, A. A., Vostrov, S. N., Lubenko, I. Y., Drlica, K., Portnoy, Y. A., & Zinner, S. H. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.5.1604-1613.2003 · Cited by 215
Mouton, J. W., Ambrose, P. G., Canton, R., Drusano, G. L., Harbarth, S., MacGowan, A., Theuretzbacher, U., & Turnidge, J. (2011) · Drug Resistance Updates · doi:10.1016/j.drup.2011.02.005 · Cited by 200
Self-citationRodríguez-Tudela, J. L., Almirante, B., Rodríguez-Pardo, D., Laguna, F., Donnelly, J. P., Mouton, J. W., Pahissa, A., & Cuenca-Estrella, M. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00296-07 · Cited by 137
Self-citationComparative Pharmacodynamics of Gentamicin against Staphylococcus aureus and Pseudomonas aeruginosa
Tam, V. H., Kabbara, S., Vo, G., Schilling, A. N., & Coyle, E. A. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01165-05 · Cited by 126
Meagher, A. K., Passarell, J. A., Cirincione, B. B., Wart, S. A. V., Liolios, K., Babinchak, T., Ellis‐Grosse, E. J., & Ambrose, P. G. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01084-06 · Cited by 123
Bhat, S. V., Peleg, A. Y., Lodise, T. P., Shutt, K. A., Capitano, B., Potoski, B. A., & Paterson, D. L. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01487-06 · Cited by 113
Clinical pharmacodynamics of quinolones
Ambrose, P. G., Bhavnani, S. M., & Owens, R. C. (2003) · Infectious Disease Clinics of North America · doi:10.1016/s0891-5520(03)00061-8 · Cited by 90
Mouton, J. W., Punt, N. C., & Vinks, A. A. T. M. M. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01586-06 · Cited by 80
Self-citationUse of Monte Carlo Simulations To Select Therapeutic Doses and Provisional Breakpoints of BAL9141
Mouton, J. W., Schmitt‐Hoffmann, A. H., Shapiro, S., Nashed, N., & Punt, N. C. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.5.1713-1718.2004 · Cited by 78
Self-citationMouton, J. W., Punt, N. C., & Vinks, A. A. T. M. M. (2005) · Clinical Therapeutics · doi:10.1016/j.clinthera.2005.06.013 · Cited by 63
Self-citationHighet, V. S., Forrest, A., Ballow, C. H., & Schentag, J. J. (1999) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/43.suppl_1.55 · Cited by 63
Bhavnani, S. M., Passarell, J. A., Owen, J. S., Loutit, J. S., Porter, S. B., & Ambrose, P. G. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.3.994-1000.2006 · Cited by 62
Drusano, G. L., D’Argenio, D. Z., Preston, S. L., Barone, C., Symonds, W., LaFon, S. W., Rogers, M., Prince, W., Bye, A., & Bilello, J. A. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.6.1655-1659.2000 · Cited by 60
Tam, V. H., & Nikolaou, M. (2011) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1001043 · Cited by 39
Chan, W. C., Li, R. C., Ling, J., Cheng, A. F., & Schentag, J. J. (1999) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/43.1.55 · Cited by 39
Goessens, W. H. F., Mouton, J. W., ten Kate, M. T., Bijl, A. J., Ott, A., & Bakker‐Woudenberg, I. A. J. M. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl529 · Cited by 35
Self-citationPharmacodynamics of Telavancin Studied in an In Vitro Pharmacokinetic Model of Infection
MacGowan, A. P., Noel, A. R., Tomaselli, S. G., Elliott, H., & Bowker, K. E. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00933-10 · Cited by 27
Self-citationKilling of Escherichia coli by β-lactams at different inocula
Tam, V. H., Ledesma, K. R., Chang, K., Wang, T.-Y., & Quinn, J. P. (2009) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2009.01.018 · Cited by 19
Cited by
Microbiological effects of sublethal levels of antibiotics
Andersson, D. I., & Hughes, D. (2014) · Nature Reviews Microbiology · doi:10.1038/nrmicro3270 · Cited by 1,757
Ecological effects of antibiotics on natural ecosystems: A review
Grenni, P., Ancona, V., & Barra Caracciolo, A. (2018) · Microchemical Journal · doi:10.1016/j.microc.2017.02.006 · Cited by 1,257
The Minimum Inhibitory Concentration of Antibiotics: Methods, Interpretation, Clinical Relevance
Kowalska-Krochmal, B., & Dudek-Wicher, R. (2021) · Pathogens · doi:10.3390/pathogens10020165 · Cited by 1,039
The negative impact of antibiotic resistance
Friedman, N. D., Temkin, E., & Carmeli, Y. (2016) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2015.12.002 · Cited by 870
Antibiotic resistance in Enterobacteriaceae: mechanisms and clinical implications
Iredell, J., Brown, J., & Tagg, K. (2016) · BMJ · doi:10.1136/bmj.h6420 · Cited by 392
Metadata
- Authors
- Mouton, J. W., Brown, D. F. J., Apfalter, P., Cantón, R., Giske, C. G., Ivanova, M., MacGowan, A. P., Rodloff, A., Soussy, C.-J., Steinbakk, M., & Kahlmeter, G.
- Venue
- Clinical Microbiology and Infection
- Publisher
- Elsevier BV
- Published
- 2012-03
- Volume
- 18
- Issue
- 3
- Pages
- E37-E45
- ISSN
- 1198-743X (ISSN-L)
- OpenAlex
- W2145484866
- Cited by
- 286
- References
- 29
- FWCI
- 6.47
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.